“Our goal is to treat patients on a more individualized basis, matching the right drugs with the right patients,” said Anil Potti, M.D., an oncologist and researcher in the DCCC and the IGSP. “The combination of these two methods, one of which uses the clinical description of patient’s breast cancer and the other which looks at gene expression at a molecular level in a patient’s tumor, may allow us to do that with unprecedented accuracy. This represents a robust approach to personalizing treatment strategies in patients suffering from breast cancer.”
The findings appear in the April 2, 2008 issue of the Journal of the American Medical Association. The study was funded by the Jimmy V Foundation, the American Cancer Society and the Emilene Brown Research Fund.
Researchers looked at almost 1000 breast tumor samples, and corresponding patient data, and applied existing technology -- a computerized system called Adjuvant! -- to assess clinical characteristics and make predictions of recurrence based on them. By then comparing gene expression in these tumor samples, the researchers were able to see specific genomic patterns among patients with aggressive cancers, and those whose cancers were less likely to recur.
“We knew from previous studies that Adjuvant! tends to overestimate disease recurrence in younger patients,” Potti said. “We hypothesized that genomic profiling could be a complementary tool that would more precisely define clinical outcomes, and could also help to aid in selecting the right drug for a given patient.”
By using the clinical and genomic tools together and cross-comparing data, the researchers were able to not only say that a particular patient has a “high” risk of recurrence, but they could be more specific; for instance, they could predict that a particular patient was 90 percent likely to see her cancer recur, Potti said.
“This is important because with this data, we might decide to treat this person more aggressively even than someone else who is considered ‘high risk’ but may have only a 60 percent likelihood of recurrence,” he said. “Moreover, we can identify specific options for chemotherapy in such patients as well, by correlating gene expression in a tumor with its response, or non-response, to certain chemotherapies.”
The findings have already been put into practice as part of several clinical trials at Duke for cancer patients. A tumor’s genomic make-up is being used to dictate the choice between a traditional chemotherapy regimen and an alternate drug that is more likely to benefit an individual patient. One such trial involving almost 300 patients with breast cancer is expected to start at Duke this spring.
Lauren Williams | EurekAlert!
New model connects respiratory droplet physics with spread of Covid-19
21.07.2020 | University of California - San Diego
Risk of infection with COVID-19 from singing: First results of aerosol study with the Bavarian Radio Chorus
03.07.2020 | Klinikum der Universität München
Scientists at the Fraunhofer Institute for Laser Technology ILT have come up with a striking new addition to contact stamping technologies in the ERDF research project ScanCut. In collaboration with industry partners from North Rhine-Westphalia, the Aachen-based team of researchers developed a hybrid manufacturing process for the laser cutting of thin-walled metal strips. This new process makes it possible to fabricate even the tiniest details of contact parts in an eco-friendly, high-precision and efficient manner.
Plug connectors are tiny and, at first glance, unremarkable – yet modern vehicles would be unable to function without them. Several thousand plug connectors...
An international research team has found a new approach that may be able to reduce bone loss in osteoporosis and maintain bone health.
Osteoporosis is the most common age-related bone disease which affects hundreds of millions of individuals worldwide. It is estimated that one in three women...
Traditional single-cell sequencing methods help to reveal insights about cellular differences and functions - but they do this with static snapshots only...
“Core-shell” clusters pave the way for new efficient nanomaterials that make catalysts, magnetic and laser sensors or measuring devices for detecting electromagnetic radiation more efficient.
Whether in innovative high-tech materials, more powerful computer chips, pharmaceuticals or in the field of renewable energies, nanoparticles – smallest...
An international research team with Prof. Cornelia Denz from the Institute of Applied Physics at the University of Münster develop for the first time light fields using caustics that do not change during propagation. With the new method, the physicists cleverly exploit light structures that can be seen in rainbows or when light is transmitted through drinking glasses.
Modern applications as high resolution microsopy or micro- or nanoscale material processing require customized laser beams that do not change during...
23.07.2020 | Event News
21.07.2020 | Event News
07.07.2020 | Event News
06.08.2020 | Power and Electrical Engineering
06.08.2020 | Life Sciences
06.08.2020 | Life Sciences